Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decitabine--bedside to bench.

Yasuhiro Oki1, Etsuko Aoki, Jean-Pierre J Issa

  • 1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. yooki-tky@umin.ac.jp

Critical Reviews in Oncology/Hematology
|October 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Blood neoplasia·2026
Same author

EZH2 and intracellular Ca<sup>2+</sup> signals interdependently coordinate alloreactive and CAR-T-cell responses.

Cellular & molecular immunology·2026
Same author

Modeling age-related methylation changes in vitro with intestinal organoids.

BMC biology·2026
Same author

DNA Methylation, Aging, and Cancer.

Epigenomes·2025
Same author

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.

Blood neoplasia·2025
Same author

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

Cancer research·2025
Same journal

Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
Same journal

Gene fusions in non-small cell lung carcinoma (NSCLC): Expert perspectives and practical considerations for routine testing.

Critical reviews in oncology/hematology·2026
See all related articles

Decitabine shows therapeutic effects in hematologic malignancies by demethylating DNA and reactivating genes. However, its clinical activity is not solely dependent on DNA hypomethylation, suggesting alternative mechanisms are also at play.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • DNA methylation is crucial in cell malignant transformation by silencing genes.
  • Decitabine, a DNA methyltransferase inhibitor, demonstrates therapeutic potential in hematologic malignancies.
  • The precise link between decitabine's clinical efficacy and its DNA demethylating activity requires further elucidation.

Purpose of the Study:

  • To review recent clinical trials of decitabine in hematologic malignancies.
  • To explore the translational research investigating decitabine's mechanism of clinical activity.

Main Methods:

  • Review of recent clinical trials involving decitabine.
  • Analysis of correlative laboratory studies from clinical trials.
  • Examination of translational research on decitabine's mechanisms.

Related Experiment Videos

Main Results:

  • Low-dose decitabine is effective in myelodysplastic syndromes, inducing global and gene-specific hypomethylation.
  • Clinical response is not directly correlated with the degree of hypomethylation beyond a certain threshold.
  • Baseline p15(INK4B) hypermethylation paradoxically correlates with a lower response rate.
  • Decitabine activates several genes independently of promoter hypomethylation.

Conclusions:

  • Decitabine's antitumor activity involves DNA hypomethylation and gene reactivation.
  • Mechanisms independent of DNA hypomethylation significantly contribute to decitabine's efficacy.